Hainan Shuangcheng’s Generic Eptifibatide Gains TGA Marketing Approval in Australia
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has received marketing approval from Australia’s Therapeutic...
May 2025
Stryker’s OptaBlate BVN System Gains FDA 510(k) Clearance
US-based Stryker (NYSE: SYK) announced this week that its OptaBlate Basivertebral Nerve Ablation (BVN) system...
Sirius Therapeutics Partners with CRISPR Therapeutics to Develop SRSD107 for Thrombosis
Sino-US biotech Sirius Therapeutics has entered into a partnership with Swiss–American biotech CRISPR Therapeutics (NASDAQ:...
Zai Lab’s ZL-1310 Receives FDA Fast Track Designation for SCLC
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) announced that it has received Fast...
Porton and Hualong Biological Partner to Advance MATC Therapy
Suzhou-based contract development and manufacturing organization (CDMO) Porton Pharma Solutions Ltd. has entered into a...
AB Science Secures Chinese Patent for Masitinib in COVID-19 Treatment
France-based AB Science SA (EPA: AB) reported receiving patent protection in China for its lead...
4B Technologies Gains NMPA Approval for ALS Drug 4B02-01 Clinical Trials
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...
Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China
US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...
Bayer’s Jivi Receives FDA Approval for Pediatric Hemophilia A Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced this week that it has received an...
Alibaba Health Reports Strong 2025 Financial Results with Revenue Hike
China-based Alibaba Health Information Technology Ltd (HKG: 0241) released its 2025 financial report for the...
CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...
Merck Sharp & Dohme Initiates Phase III Trial of Ifinatamab Deruxtecan for Esophageal Cancer
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) announced the first patient dosing in...
Terumo Corporation Acquires WuXi Biologics’ Germany Plant for EUR 150 Million
Japan-based Terumo Corporation (TYO: 4543) has entered into an agreement with China-based Contract Research, Development...
Grand Pharma’s Chengdu RDC Megafactory Secures Class A Radiation Safety License
Grand Pharmaceutical Group Limited (HKG: 0512) has obtained a Class A Radiation Safety License from...
Shanghai Henlius Biotech Doses First Patient in Phase I/III Study of HLX13 for Hepatocellular Carcinoma
Shanghai Henlius Biotech Inc. (HKG: 2696) announced the completion of first patient dosing in a...
Shanghai MicroPort’s Minos Stent Graft Secures Egyptian Marketing Approval
China’s Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced that it has received...
Sino Biopharmaceutical’s QP001 (Meloxicam) Approved by NMPA and FDA for Postoperative Pain
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced that its Category 2.2 drug QP001 (meloxicam) has...
Porton Pharma Partners with Tong Eye on iPSC-Derived RPE Cell Therapies for Ophthalmic Diseases
Chinese CDMO leader Porton Pharma Solutions Ltd. has entered into a strategic partnership with domestic...
InnoCare Pharma Doses First Patient in Phase II/III Trial of TYK2 Inhibitor for Vitiligo
Chinese biotech InnoCare Pharma (HKG: 9969, SHA: 688428) has administered the first patient dose in...
Suzhou’s PegBio Launches Hong Kong IPO Amid Pipeline Progress
Suzhou-based endocrine-metabolism biotech PegBio Co., Ltd. (HKG: 2565) has successfully launched its Hong Kong IPO,...